Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
about
Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1Tumor Associated Macrophages in Kidney CanceruPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer.Do serum biomarkers really measure breast cancer?Increased expression of urokinase plasminogen activator and its cognate receptor in human seminomasQuantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function.Current status of the prognostic molecular biomarkers in breast cancer: A systematic reviewMatrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulationFar beyond the usual biomarkers in breast cancer: a review.Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells.The changing role of pathology in breast cancer diagnosis and treatment.Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cellsuPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancerNon-invasive proteomics-thinking about personalized breast cancer screening and treatmentDevelopment of a Mammalian suspension culture for expression of active recombinant human urokinase-type plasminogen activator.Increased Umbilical Cord PAI-1 Levels in Placental Insufficiency Are Associated with Fetal Hypoxia and Angiogenesis.Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases.Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover.Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients.Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR)Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.Tumor markers in clinical practice: a review focusing on common solid cancersCorrelation between metastatic potential and variants from colorectal tumor cell line HT-29.Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system.The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.Statistical optimization of fibrinolytic enzyme production by Pseudoalteromonas sp. IND11 using cow dung substrate by response surface methodologyProstate cancer cells show elevated urokinase receptor in a mouse model of metastasis.Mammary gland biology and breast cancer. Conference on Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer Progression.Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer.Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Anti-Metastatic Effects of Antrodan with and without Cisplatin on Lewis Lung Carcinomas in a Mouse Xenograft Model.
P2860
Q27666429-72CF4B57-A54F-469C-80E1-AAA7EFD49145Q28071990-5B0725CD-6E14-4DBC-9E63-7A0BA15A3503Q33376876-B1A34DBA-AD9F-4E15-9729-D28C956066FDQ33454967-CA61157B-BA7E-4E7A-B331-2546B5810B3CQ33559079-1D4EC564-EDD0-4658-87BA-7E96081AD6CEQ33597170-9BC59FEF-12A0-46A3-A398-8E26941A9F6DQ33598494-AE1F6116-2E01-47E7-9501-7F4D2DEE597DQ33619919-1EDA0CBB-3AC6-4BE4-8A93-495E8FCDBA15Q33782164-FF475766-09D9-47AD-920D-291147861DC1Q33935217-BEDC55EA-67B7-410B-9ACE-3651EF148F83Q34148127-00F39C1F-9780-44F8-8858-8EB86913FDFBQ34887726-63F0EA8E-28F3-4039-A195-D5491841CC07Q35067751-11000003-C4F7-4B14-985B-27057389C49CQ35082260-5F506311-C321-4E00-B5B0-C3666ADE455DQ35159014-1343EE0B-9879-431B-9326-340D51FCF860Q35220266-57F2DF02-5480-4B05-AE87-CF5B23B2E802Q35720929-826B8BED-C45A-4C25-A789-8496D12F6D05Q35769956-6A4F7C70-D2F9-40E4-8891-2CBD457ADB8FQ36117711-61EF2147-6B81-4831-A0F3-A50520293F73Q36255134-9B68914B-1AE7-4FE2-9C0E-1F21E1256887Q36557018-D73E9260-57CB-4470-876F-013CA19F9AA4Q36557197-8FC6B3C2-4830-47C4-BCB1-7DE620053370Q36609747-E2BE1FCE-FDFB-47DE-9C36-25438D37E32DQ36640228-96B95ECD-5B43-4AC7-A0C7-D0AFBF831347Q36790876-3780F022-8D3B-45B4-8680-8268093CEEF4Q37135253-4B7907C0-3980-44A9-8E71-78B7DFB8A5A1Q37244935-74DB72AE-D2BF-4450-A327-EF28F111A2ADQ37642197-996271C6-AC63-4133-B010-D64D49764546Q38010046-0A208B20-E738-4DD4-985E-2EE07B13C918Q40618623-CECBD591-F687-46CD-9757-7B3285763A62Q41465764-7A90DF89-7171-44A2-A1A4-FE749B694CD0Q41826247-1BD96948-6962-4AC8-B617-F85EDAB73617Q41905619-A4EF74CB-35D6-4A63-AFCD-6F8A59CF25E7Q41917864-0350BAF9-3D9D-41FC-9BC6-E1732AA10F50Q43097641-85742C24-036F-4BED-BE75-F999CB833471Q43150193-829366EA-6410-4395-9471-2A798A4F6FFEQ47400340-6F1B28BA-5FE0-4F94-995E-51E537A9EA78Q48222816-897A609E-B0AE-42B0-B3B4-B740A3341195Q54960825-C2E49A62-E0A4-4663-A1A7-F6367A4860ACQ54978344-BA40E97F-75CB-48B6-B64F-CA985B1EA650
P2860
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@ast
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@en
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@nl
type
label
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@ast
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@en
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@nl
prefLabel
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@ast
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@en
Urokinase plasminogen activato ...... t to level 1 evidence studies.
@nl
P1433
P1476
Urokinase plasminogen activato ...... ot to level 1 evidence studies
@en
P2093
Michael J Duffy
P304
P407
P577
2002-08-01T00:00:00Z